Gilde leads €25m series-C for Stat-Diagnostica

Existing investors Kurma Partners, Ysios Capital, Idinvest Partners, Boehringer Ingelheim, Caixa Capital Risc and Axis Capital took part in the funding round.

The fresh capital will allow the company to accelerate its market strategy and to prepare the launch of its DiagCore product in the European market in 2017.

Previous funding
In June 2011, Spanish venture capital firms Axis and Ysios contributed to a €2m series-A round of funding for the business.

In May 2013, Kurma led a €17m series-B round alongside Axis, Boehringer Ingelheim, Caixa Capital Risc, Idinvest and Ysios.

Company
Founded in 2010 and headquartered in Barcelona, Stat-Diagnostica operates in the patient-testing sector for critical-care situations, including emergency medicine units within hospitals.

Its DiagCore product is a decentralised molecular testing device, which performs in-vitro diagnostics and aims to improve the decision-making process and reduce costs. The business employs 30 staff.

People
Gilde Healthcare – Arthur Franken (partner).
Stat-Diagnostica – Jordi Carrera (co-founder, CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Healthcare
• Southern Europe
• Spain
• Gilde Investment Management
• Caixa Capital Risc
• Ysios Capital
• IDInvest Partners (AGF Private Equity)
• Axis Participaciones Empresariales
• Venture